Sarepta Therapeutics has beaten earnings estimates in 3 of the last 4 quarters and generates free cash flow equal to 315% of net income, but is almost entirely dependent on its Duchenne muscular dystrophy product franchise and trades in a technical recovery pattern with 29% short interest and a weak overall score of 4.6 out of 10 reflecting concentrated product risk.
Thesis pillars
- Duchenne Franchise Cash Generation→Stable
- Analyst Consensus Meaningful Upside→Stable
- Product Supplier Concentration Binary Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 2, 2026· older than 90 days
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum.
Sarepta Therapeutics develops RNA-targeted and gene therapies for rare muscular diseases, with four FDA-approved products—EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS—all targeting Duchenne muscular dystrophy. The company recorded $1,864.3 million in net product revenues in... Read more
Sell if holding. Engine safety override at $18.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 4/8 gates (clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 1d<=7d. Suitability: speculative.
About Sarepta Therapeutics, Inc.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics generated $1,864.3 million in net product revenues in 2025 from four FDA-approved Duchenne muscular dystrophy treatments: EXONDYS 51 (exon 51 skipping, launched 2016), VYONDYS 53 (exon 53 skipping, launched 2019), AMONDYS 45 (exon 45 skipping, launched 2021), and ELEVIDYS, an AAV gene therapy that received traditional FDA approval for ambulatory patients in June 2024 and accelerated approval for non-ambulatory patients the same month.
Sarepta distributes PMO products through a limited home-infusion specialty pharmacy network and a specialty distributor serving hospitals and outpatient clinics; ELEVIDYS flows through third-party logistics providers and a limited specialty pharmacy network for in-hospital infusion. The company currently lacks internal GMP manufacturing capability and relies on Catalent for commercial supply of ELEVIDYS and the SRP-9003 LGMD program, while Aldevron supplies plasmid material for ELEVIDYS and SRP-9003. Reimbursement coverage for ELEVIDYS has been restricted by certain payors following the 2025 safety events, and the ESSENCE confirmatory trial reported topline failure to meet its primary endpoint on November 3, 2025, creating regulatory uncertainty for AMONDYS 45 and VYONDYS 53 under the FDA's accelerated approval pathway. Pipeline programs include SRP-1001 (FSHD) and SRP-1003 (DM1) in Phase 1/2a through the Arrowhead Collaboration Agreement signed in November 2024.
Show full overview
Two simultaneous regulatory pressures compound uncertainty around the product portfolio. The ESSENCE trial for AMONDYS 45 and VYONDYS 53 failed to achieve statistical significance on its primary endpoint, which the 10-K notes could lead to label changes, revocation of accelerated approvals, or directives to remove those products from the market. Concurrently, ELEVIDYS carries a boxed warning for acute liver injury and acute liver failure added in November 2025, with the non-ambulatory indication removed from the Prescribing Information, making resumption of dosing in that population subject to an additional FDA review process dependent on sirolimus immunosuppressant trial data.
See also: Healthcare · Biotechnology
From Sarepta Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Oct 27, 2026Recent Developments — Sarepta Therapeutics, Inc.
Latest news
- NEWS Sarepta Therapeutics Announces Participation in Upcoming Investor Conferences — fiscal.ai Oct 27, 2026 neutral
- NEWS Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results — fiscal.ai Oct 22, 2026 neutral
- NEWS Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat — MarketBeat Aug 8, 2026 negative
- NEWS Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - TradingView — TradingView Aug 6, 2026 positive
- NEWS Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat — MarketBeat Aug 6, 2026 neutral
Latest item Oct 27, 2026 · Generated 2026-11-04T11:59:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductDuchenne products10-K Item 1: 'we have developed and commercialized the following four approved products for the treatment of Duchenne'
- HIGHSupplierCatalent10-K Item 1: 'Catalent supports our clinical and commercial manufacturing demand for ELEVIDYS and our SRP-9003 LGMD program'
- MEDIUMSupplierAldevron10-K Item 1: 'Aldevron provides plasmids for ELEVIDYS and SRP-9003 and is expected to provide plasmid source material for any future gene therapy programs'
Material Events(8-K, last 90d)
- 2026-06-04Item 5.02LOWJune 4, 2026 annual meeting: stockholders approved 2026 Equity Incentive Plan (6,286,841 shares, supersedes 2018 plan) and 2026 Employee Stock Purchase Plan (1,500,000 shares, supersedes 2013 ESPP). No officer departures or elections noted.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -6.9%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $17.24. Score 5.3/10, moderate confidence.
Analyst target: $19.47 (+5.0% upside). Prior stop was $17.24. Stop-loss: $17.24.
Concentration risk — Product: Duchenne products; Concentration risk — Supplier: Catalent; Quality below floor (2.8 < 4.0).
Sarepta Therapeutics, Inc. trades at a P/E of N/A (forward 7.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
31 analysts rate SRPT, with a consensus score of 3.4/5. 22 analysts publish price targets averaging $22.
What does Sarepta Therapeutics, Inc. do?Sarepta Therapeutics develops RNA-targeted and gene therapies for rare muscular diseases, with four FDA-approved...
Sarepta Therapeutics develops RNA-targeted and gene therapies for rare muscular diseases, with four FDA-approved products—EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS—all targeting Duchenne muscular dystrophy. The company recorded $1,864.3 million in net product revenues in 2025, distributed through specialty pharmacy and hospital networks in the U.S.